We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Pfizer to Seek Full Approval of Its COVID-19 Vaccine This Month

Pfizer to Seek Full Approval of Its COVID-19 Vaccine This Month

May 5, 2021

Pfizer said yesterday that it plans to file for full approval of its COVID-19 vaccine by the FDA later this month — an approval that would allow the companies to market the vaccine directly to consumers and allow the product to stay on the market beyond the pandemic.

The FDA granted Emergency Use Authorization (EUA) for the vaccine, co-developed with BioNTech, on Dec. 11, 2020, for individuals 16 years of age and older, but the authorization is only good through the end of the public health emergency.

A Pfizer spokesperson confirmed yesterday that the company expects to submit a Biologics License Application (BLA) to the FDA this month seeking full approval for the vaccine. For a full approval, the agency will require six months’ worth of supporting data, compared with just 2 months for an EUA.

The FDA is expected to revise the Pfizer EUA by early next week to include teenagers ages 12 to 15. The drugmakers filed for an updated EUA after reporting that the vaccine showed 100 percent efficacy for this population in a phase 3 U.S. trial of 2,260 participants. The vaccine also induced strong antibody responses and was well-tolerated, the companies said (DID, April 1).

The FDA declined to comment on the timing of an amended EUA but said it is “working to review this request as quickly and transparently as possible.”

Pfizer is also preparing a booster shot aimed at combating variants of SARS‑CoV‑2, with an EUA for the new shot expected later this year. To support that submission, the two companies launched a study in February evaluating the safety and immunogenicity of a retooled third dose of their vaccine against new variants (DID, Feb. 26).

Pfizer is also planning to launch a new study assessing the co-administration of its COVID-19 vaccine with an influenza vaccine candidate, with results expected during this year’s third quarter. — Jason Scott

COVID-19

Upcoming Events

  • 08Feb

    Process and Design Validation for Devicemakers: A Deep Dive into Best Practices, Recent Trends and Regulatory Definitions

  • 09Feb

    The Inextricable Link Between Data Integrity and Quality Culture

  • 15Feb

    Advanced Compliance Writing CAPA: Mastering Failure Investigation and Root Cause Analysis

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 22Feb

    Best Practices for Developing and Maintaining a GxP Training Matrix

  • 07Mar

    FDA’s Remote Assessments v. Remote Interactive Evaluations: Do You Really Know the Difference?

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • MedTrace Receives U.S. Patent for Heart Modeling Method

  • NICE Recommends Epidyolex for Tuberous Sclerosis Complex Seizures

  • Consortium Gets EU Funding to Develop Continuous Blood Pressure Monitoring Device

  • FDA Approves GSK’s Oral Drug for Chronic Kidney Disease-Related Anemia

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell or Share My Data
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing